Novozymes A/S (OTCMKTS:NVZMY – Get Free Report)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $56.89, but opened at $59.69. Novozymes A/S shares last traded at $58.38, with a volume of 9,414 shares.
Novozymes A/S Stock Up 2.0%
The stock has a market cap of $24.07 billion, a price-to-earnings ratio of 41.47, a PEG ratio of 1.02 and a beta of 1.11. The stock has a 50 day simple moving average of $59.60 and a 200 day simple moving average of $61.50. The company has a quick ratio of 1.00, a current ratio of 1.61 and a debt-to-equity ratio of 0.26.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.44). Novozymes A/S had a return on equity of 6.38% and a net margin of 13.96%.The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.22 billion. As a group, analysts expect that Novozymes A/S will post 1.82 earnings per share for the current fiscal year.
Novozymes A/S Company Profile
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
Featured Stories
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
